• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evercore ISI initiated coverage on Dyne Therapeutics with a new price target

    5/29/25 8:17:44 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    Evercore ISI initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $46.00
    Get the next $DYN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    3/7/2025$50.00Sector Outperform
    Scotiabank
    12/13/2024$46.00Outperform
    Robert W. Baird
    11/26/2024$45.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Cox John sold $54,201 worth of shares (4,060 units at $13.35), decreasing direct ownership by 3% to 142,179 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:07:07 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Kerr Douglas sold $17,916 worth of shares (1,342 units at $13.35), decreasing direct ownership by 1% to 92,815 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:05:18 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Friedl-Naderer Johanna sold $1,949 worth of shares (146 units at $13.35), decreasing direct ownership by 0.15% to 95,911 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:03:04 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care